Oncotarget

Clinical Research Papers:

Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma

Ying Wang, Chang-Long Chen, Qiu-Zhong Pan, Ying-Yuan Wu, Jing-Jing Zhao, Shan-Shan Jiang, Jie Chao, Xiao-Fei Zhang, Hong-Xia Zhang, Zi-Qi Zhou, Yan Tang, Xu-Qiong Huang, Jian-Hua Zhang and Jian-Chuan Xia _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:6323-6334. https://doi.org/10.18632/oncotarget.6319

Metrics: PDF 1213 views  |   HTML 1187 views  |   ?  


Abstract

Ying Wang1,3,*, Chang-Long Chen1,*, Qiu-Zhong Pan1, Ying-Yuan Wu4, Jing-Jing Zhao1, Shan-Shan Jiang1, Jie Chao3, Xiao-Fei Zhang1, Hong-Xia Zhang1, Zi-Qi Zhou1, Yan Tang1, Xu-Qiong Huang3, Jian-Hua Zhang2 and Jian-Chuan Xia1

1 Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China

2 Department of Health Service Management, Guangzhou University of Chinese Medicine, Guangzhou, China

3 Department of Epidemiology and Health Statistics, Guangdong Key Laboratory of Molecular Epidemiology, Guangdong Pharmaceutical University, Guangzhou, China

4 Department of Gynaecology and Obstetrics, Panyu Branch of Armed Police Corps Hospital of Guangdong, Guangzhou, China

* These authors have contributed equally to this work

Correspondence to:

Jian-Chuan Xia, email:

Jian-Hua Zhang, email:

Keywords: TPD52, hepatocellular carcinoma, prognosis, tumor suppressor, mechanism

Received: May 26, 2015 Accepted: October 22, 2015 Published: November 13, 2015

Abstract

Tumor protein D52 (TPD52) has been indicated to be involved in tumorigenesis of various malignancies. But its role in hepatocellular carcinoma (HCC) is unknown. This study aimed to explore the expression of TPD52 in HCC samples and cell lines using real-time quantitative PCR, western blotting, and immunohistochemistry. The prognostic value of TPD52 in HCC was also analysed. Meanwhile, the mechanism of TPD52 in hepatocarcinogenesis was further investigated by western blotting, immunohistochemistry, over-express and knockdown studies. We found that TPD52 expression was significantly decreased in the HCC tissues and HCC cell lines. TPD52 expression was significantly correlated with tumor-nodes-metastasis (TNM) stage. Kaplan–Meier survival curves showed that high TPD52 expression was associated with improved overall survival (OS) and disease-free survival (DFS) in HCC patients. Multivariate analysis indicated that TPD52 expression was an independent prognostic marker for the OS and DFS of patients. In addition, TPD52 expression was positively correlated with p21 and p53 expression, and was negatively correlated with MDM2, BCL2 and P-GSK-3β expression in HCC. In conclusions, our findings suggested that TPD52 is a potential tumor suppressor in HCC. It may be a novel prognostic biomarker and molecular therapy target for HCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6319